Get the Stockscreener App
11.81
2.23%
-0.295
Replimune Group Inc stock is traded at $11.81, with a volume of 140.81K.
It is down -2.23% in the last 24 hours and down -17.14% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
See More
Previous Close:
$12.11
Open:
$12.18
24h Volume:
140.81K
Relative Volume:
0.21
Market Cap:
$932.65M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-3.7389
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+0.85%
1M Performance:
-17.14%
6M Performance:
+6.38%
1Y Performance:
+31.85%
1-Day Range:
$11.77
$12.64
1-Week Range:
$10.68
$12.64
52-Week Range:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
11.81 | 932.65M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.64 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.40 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.21 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.80 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Financial Metrics Check: Replimune Group Inc (REPL)’s Ratios for Trailing Twelve Months - The Dwinnex
Replimune Group Appoints New Director, Grants Stock Options By Investing.com - Investing.com Australia
Replimune Group Appoints New Director, Grants Stock Options - Investing.com
Replimune Group Appoints Michael Goller To Board, Increases Board Size To Ten -March 07, 2025 at 05:04 pm EST - Marketscreener.com
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 04:11 pm EST - Marketscreener.com
Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World
Replimune Group (NASDAQ:REPL) Stock Price Up 6.1%What's Next? - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat
Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com
Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St
Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World
FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat
Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat
Replimune stock target raised to $22 at H.C. Wainwright - MSN
Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN
Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia
Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha
Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com
Replimune Group Inc. (REPL) reports earnings - Quartz
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
FDA Fast-Tracks Replimune's Melanoma Treatment as Cash Reserves Hit $536M in Q3 Report - StockTitan
Top Wealth Group Holding Ltd (TWG)’s financial ratios: A comprehensive overview - The Dwinnex
Metric Analysis: Nvni Group Ltd (NVNI)’s Key Ratios in the Limelight - The Dwinnex
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
How to Take Advantage of moves in (REPL) - Stock Traders Daily
Replimune's Strategic Move: $14.25 Stock Options Package Secures Top Talent - StockTitan
Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World
Holdings of Replimune Group Inc (REPL) are aligned with the stars - SETE News
SG Americas Securities LLC Acquires 3,374 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Was there any good news for Replimune Group Inc (REPL) stock in the last session? - US Post News
Upward Trajectory: Replimune Group Inc (REPL) Posts a Slidee, Closing at 13.71 - The Dwinnex
Vanguard Group Inc's Strategic Acquisition of Replimune Group In - GuruFocus.com
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Average Target Price from Analysts - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Consensus PT from Analysts - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Down 3.5%What's Next? - MarketBeat
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):